Connection

ANANTH ANNAPRAGADA to Alzheimer Disease

This is a "connection" page, showing publications ANANTH ANNAPRAGADA has written about Alzheimer Disease.
Connection Strength

1.133
  1. A surrogate marker for very early-stage tau pathology is detectable by molecular magnetic resonance imaging. Theranostics. 2022; 12(12):5504-5521.
    View in: PubMed
    Score: 0.470
  2. Intravenous delivery of targeted liposomes to amyloid-? pathology in APP/PSEN1 transgenic mice. PLoS One. 2012; 7(10):e48515.
    View in: PubMed
    Score: 0.240
  3. Advances in nanoprobes for molecular MRI of Alzheimer's disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Mar-Apr; 16(2):e1946.
    View in: PubMed
    Score: 0.131
  4. 1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded a-Synuclein Aggregates. ChemMedChem. 2022 01 19; 17(2):e202100611.
    View in: PubMed
    Score: 0.112
  5. Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease. Sci Rep. 2020 09 30; 10(1):16185.
    View in: PubMed
    Score: 0.104
  6. Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy. Transl Res. 2016 09; 175:37-53.
    View in: PubMed
    Score: 0.076
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.